51 results about "Cellular transplantation" patented technology

The present invention provides a method for treating an injury of a spinal cord of a patient. The method includes implanting a therapeutic substance in the spinal cord under indirect visualization. The indirect visualization may be provided by an endoscope, and the therapeutic substance may include cells. The present invention also provides a device for treating an injury of the spinal cord. The device includes skin visualization means for visualizing the spinal cord through a skin puncture, and injection means for injecting a therapeutic substance into the spinal cord.

The present invention relates to non-lethal methods of conditioning a recipient for bone marrow transplantation. In particular, it relates to the use of nonlethal doses of total body irradiation, total lymphoid irradiation, cell type-specific or cell marker-specific antibodies, especially antibodies directed to bone marrow stromal cell markers, NK cells, or the CD8 cell marker, cytotoxic drugs, or a combination thereof. The methods of the invention have a wide range of applications, including, but not limited to, the conditioning of an individual for hematopoietic reconstitution by bone marrow transplantation for the treatment of hematologic malignancies, hematologic disorders, autoimmunity, infectious diseases such as acquired immunodeficiency syndrome, and the engraftment of bone marrow cells to induce tolerance for solid organ, tissue and cellular transplantation.

An immunoisolation patch system, and particularly a patch system comprising multiple immunoisolation microcapsules, each encapsulating biological material such as cells for transplantation, which can be used in the prophylactic and therapeutic treatment of disease in large animals and humans without the need for immunosuppression.

Myoblast cells obtained by culturing, particularly from satellite cells or other progenitor cells, are transplanted into tissue such as diseased heart tissue to form healthy repair tissue and reverse disease. This technique can be carried out in various ways and preferably includes a cellular integration factor to assist cellular survival, integration and longevity into the treated organ. Angiogenesis factors such as vascular endothelial growth factor are particularly preferred and may be transgenically expressed by the transplanted cell. Other factors that may be used to augment the procedure include migratory and scaffolding molecules. The methods and materials are particularly useful in combination with an automated cell processor and an automated catheter delivery system. The materials and methods for their use may be applied to the prophylaxis and therapy of damaged hearts, using cells originally obtained from the patient, another human, or another animal.

The present invention relates to non-lethal methods of conditioning a recipient for bone marrow transplantation. In particular, it relates to the use of nonlethal doses of total body irradiation, total lymphoid irradiation, cell type-specific or cell marker-specific antibodies, especially antibodies directed to bone marrow stromal cell markers or the CD8 cell marker, cytotoxic drugs, or a combination thereof. The methods of the invention have a wide range of applications, including, but not limited to, the conditioning of an individual for hematopoietic reconstitution by bone marrow transplantation for the treatment of hematologic malignancies, hematologic disorders, autoimmunity, infectious diseases such as acquired immunodeficiency syndrome, and the engraftment of bone marrow cells to induce tolerance for solid organ, tissue and cellular transplantation.

The invention discloses a tissue engineering material-based culture method and applications of melanophore. In the method of the invention, the tissue engineering technology is used to build carrier material with good biocompatibility and perform culture (co-culture) and transfer of melanophore or melanophore, fibroblast and keratinocyte and the method can be used in depigmentation diseases such as vitiligo and for the regulation of skin color. The invention relates to the preparation of the carrier material with biocompatibility and the building and transplanting of the cell-carrier composite material. The carrier material can be used to provide good carrier for cell culture, maintain cellular activity and solve the problem that the cell suspension is easy to lose in the cellular transplantation process; the inoculum density and culture time of cells can be regulated at the same time, the regulation to the skin colors of different individuals can be realized; and the carrier materialhas good performances such as damage resistance, tear resistance and easy transfer, has good function of promoting wound healing, and satisfies the use requirements of the large-area depigmentation disease and the regulation of skin color.

This application discloses alginate microencapsulation-mediated differentiation of embryonic stem cells and use of the stem cell differentiation method for the development of effective treatment of various diseases and disorders. The microencapsulation of embryonic stem (ES) cells results in decreased cell aggregation and enhanced neural lineage differentiation through incorporating the soluble inducer retinoic acid (RA) into the permeable microcapsule system. This application also discloses a micro-encapsulation system for immobilizing mesenchymal stromal cells (MSCs) while sustaining the molecular communication. Thus, the invention provides the use of encapsulated mesenchymal stromal cells in the cellular transplantation therapies. Moreover, the invention provides methods for delivery of encapsulated MSCs into the central nervous system and therapies derived therefrom, such as, the treatment of spinal cord injury (SCI) and other inflammatory conditions.

The present invention is related to a composition for the treatment of articular cartilage damage or loss or defect. The composition for the treatment of articular cartilage injury of the present invention is characterized by that it is composed of cellular components separated, proliferated, and / or differentiated from the umbilical cord blood and their media, or of the above cellular components, their media, and biocompatible polymers. Compared to the conventional cells used for the treatment of articular cartilage damage, cellular components of the composition of the present invention have very superior ability of proliferation and differentiation and more easy to be collected and acquired. And the polymers of the composition of the present invention have one or more characteristics among the biocompatibility, biodegradation property and possible ability to serve to enhance nutrition of cells and possible ability to enhance formation of intercellular substrate as well as the mechanical strength and flexibility to the degree which is proper for cellular transplantation and generation of cartilage tissues.

The present invention provides a method that embryo of human embryonic stem cells (HES) is directionally induced and divided into liver cells. First, the biological property of high degree of self-regeneration multiplication of HES cell is made use of, the collagenase IV digestion is adopted for transfer of culture and augmentation, thereby obtaining a plurality of stem cells; second, the HES cell is inoculated into a cell utensil with lower adsorbability to form a mature imitated embryonic plant (EB); third, the mature cystic EB is digested with 0.25 tryptic enzyme to 0.02 percent EDTA to a single cell, and then is inoculated to a tissue culture dish which is packed with I-shaped collagen in advance, solution culture is induced under the condition of dexamethasone and human trypsin, and the differentiation towards the liver cell direction is observed and judged. The prevent invention provides the method that the HES is efficiently divided into liver cells, at the same time, the method makes the follow-up judging work more simply and more efficient, and lay a foundation for the stem cellular transplantation or biologic artificial liver curing the disease such as serious hepatitis, hepatic failure and so on.

This invention relates to an immunoisolation encapsulation system that protects cellular transplants and thus allows cell function and survival without the need of immunosuppression. The immunoisolation system is a multi-component, multi-membrane capsule that allows optimization of multiple design parameters independently for reproducible functions in large animals models.

An electromagnetic field is applied to transplanted cells during their transplantation culturing to a chi eve confluence and alignment of transplanted cells into damaged tissue and organs, therefore improving the synchronization of electrical and mechanical tissue or organ functions. The electromagnetic field may be applied by catheter based to a selected portion of tissue or to the entire surface of a hollow body cavity or organ, such as heart chamber. The electromagnetic field is provided by an expansible net or array from a catheter or on an inflatable balloon or stent. The electromagnetic field is also provided by an implantable net or array of electrodes which may either be hardwired to a pulse generator or coupled by means of wireless or inductive transmission.

An immunoisolation patch system, and particularly a patch system comprising multiple immunoisolation microcapsules, each encapsulating biological material such as cells for transplantation, which can be used in the prophylactic and therapeutic treatment of disease in large animals and humans without the need for immunosuppression.

The invention discloses an in vitro culture method for human embryonic olfactory mucosa neural stem cells. Adequate olfactory neural stem cells, olfactory neural precursor cells and olfactory ensheathing precursor cells are obtained by establishing the in vitro culture for the human embryonic olfactory mucosa neural stem cells, and are applied to the clinical treatment and fundamental research of cellular transplantation of central lesion.

The invention relates to a medicine for curing osteonecrosis, belonging to the field of regenerative medicine engineering. Human amniotic mesenchymal cells (hAMCs) are used as cell source for cellular transplantation and tissue organization so as to cure the osteonecrosis and to provide a new way for repairing a damaged osseous tissue and reorganizing tissues. Based on the multi-lineage differentiation potential of the hAMCs, osteocytes, osseous tissues and vascular endotheliums can be differentiated in the human body, thereby completing the processes of osteanagenesis, bone remodeling and vascularization and forming a new osseous tissue integrated with the tissues of the patient.

The invention discloses a novel method for the in-vitro liver cell differentiation of human marrow mesenchyme stem cells based on VPA inducement. The human marrow is used as a raw material, the mesenchyme stem cells of the human marrow are separated, a fibroblast growth factor 4, a hepatocyte growth factor, tumour suppressing essence and dexamethasone are sequentially added after the VPA processing of histone ab-acetylase suppressor valproic acid, the liver cells of the human marrow are induced to be differentiated, and a class of polygonal liver cell type cells which have the biological functions of the liver cells of synthesis glycogen, urea, secretion albumin and the like and have double cores are obtained. The method enhances the efficiency of the liver cell differentiation of the human marrow mesenchyme stem cells greatly, provides a novel technology and opens up a novel approach for developing and applying the human marrow mesenchyme stem cells to the cellular transplantation treatment of liver diseases, hepatic tissue engineering and the like and also provides a novel research model for the research of liver cell differentiation development molecular mechanisms comprising a surface appearance genetic mechanism and the like.

The invention provides a Chinese sturgeon boule gene sequence and application thereof. A Chinese sturgeon boule gene has a cDNA (complementary Desoxvribose Nucleic Acid) sequence which is 2585bp in total length, has an open reading frame which is1065bp, codes 354 amino acids, and has a nucleotide sequence shown as SEQ ID No.1 and an amino acid sequence shown in SEQ ID No.2. The Chinese sturgeon boule gene sequence can be applied to identification, tracing and separation of germ cells of Chinese sturgeon, and lays a foundation for application and research on aspects of germ cellular transplantation, germplasm resource storage and the like of the Chinese sturgeon.

Embodiments of the invention relate generally to methods of diagnosing, classifying, and / or identifying a patient's risk of developing graft versus host disease, including severe or lethal graft versus host disease, after receiving hematopoietic cellular transplantation, a transfusion or a transplantation, but before the onset of clinical symptoms.

The present invention provides a method for treating an injury of a spinal cord of a patient The method includes implanting a therapeutic substance in the spinal cord under indirect visualization. The indirect visualization may be provided by an endoscope, and the therapeutic substance may include cells. The present invention also provides a device for treating an injury of the spinal cord. The device includes skin visualization means for visualizing the spinal cord through a skin puncture, and injection means for injecting a therapeutic substance into the spinal cord.

The invention discloses a method for promoting reprogramming of mouse fibroblasts into myocardial cells under low oxygen conditions. A reprogramming factor is utilized to directly reprogram mouse fibroblasts into efficiently differentiated myocardial cells; on such basis, the efficiency of low oxygen on direct reprogramming to generate myocardial cells and the variation of the HIF-1 expression level in the reprogramming process from fibroblasts to myocardial cells are detected, and the effect of low oxygen on the cell direct reprogramming is systematically explained. The expression conditions of the multi-potential transcription factor and epigenetic regulation factor under low oxygen stimulation are detected. The individualized myocardial cells obtained by directly reprogramming body cells are used for repairing myocardial infarction, thereby laying a foundation for enhancing the clinical cellular transplantation efficiency and safety. The research of the relationship between the low oxygen microenvironment and reprogramming provides a new idea for researching the reprogramming mechanism under low oxygen conditions.

The invention discloses a method for preparing a mononuclear cell pre-transplantation state. Waste umbilical cord blood of a healthy person is collected in a bacteria-free mode, blood plasma is separated, normal saline is used for diluting a cellular layer, a density gradient separation method is used for separating a mononuclear cell, using separated umbilical cord blood plasma to perform dilution and heavy suspension and after the mononuclear cell is washed, the concentration of the mononuclear cell is adjusted, and the mononuclear cell is sealed in a blood plasma bag and in a state before application. The method is different from existing methods in processing program, reduces the types, the number and the time of reagents contacted with the mononuclear cell, does not need the steps of cultivation, passage, cryopreservation and the like, and avoids the influence of other reagents contacted with the mononuclear cell to survival and growth of the mononuclear cell. The method uses the umbilical cord blood plasma to obtain the umbilical cord blood mononuclear cell which is subjected to final dilution, heavy suspension and washing, enables the umbilical cord blood mononuclear cell to be in a growing-environment state before collection and application, enables extracorporeal time of the umbilical cord blood mononuclear cell to shortened by 1.5 hours, has great promoting effect on vitality, survival and growth of the cell and meets the application requirement for various inspections before the application.

The present invention relates to the treatment of brain damage by cellular transplantation. According to one aspect of the invention, a method for treating a motor, sensory and / or cognitive deficit comprises administering a composition comprising pluripotent cells into the damaged brain in a region contra-lateral to that containing the site of damage. The cells are preferably conditionally immortal.

The present disclosure is directed to systems, methods, and compositions for functional interaction of fibroblasts with one or more types of immune cells such that the interaction results in modification to the fibroblasts, the one or more types of immune cells, or both. In some embodiments, one or more certain agents are also utilized during the interaction or in lieu of one of the types of cells. In specific embodiments, cells to be used in cellular transplantation therapy are modified to have reduced immunogenicity.

The invention discloses application of UL16 protein in preparation of a small molecular medicine for promoting in-vitro differentiation of embryonic stem cells, and application of stem cell transplantation in treatment of nervous system degenerative diseases. According to the invention, by construction of UL16 plasmids to transfect host cells, the fact that UL16 can promote aerobic oxidation and oxidative phosphorylation of glucose and activate the cell productivity pathway so as to increase the intracellular ATP content and improve mitochondrial functions is found. Finally, by construction ofUL16 expression plasmids to transfect mouse embryonic stem cells, mitochondrial function state enhancement and energy metabolism enhancement are found, and stem cell differentiation can be promoted.Clinical treatment of cells in a differentiation defect state and cells with a low differentiation rate is realized; and the UL16 protein is used for treating related diseases or pathological and physiological processes of mitochondrial dysfunction or hypofunction of the cells.

The invention belongs to the technical field of tissue repair medicines, and particularly relates to application of a TGF-beta inhibitor in preparation of a medicine for treating diabetic foot. Aiming at the problems that cells are easy to apoptosis and the treatment effect of cell transplantation is not lasting when the cells are used for treating the diabetic foot, the invention provides the application of the TGF-beta inhibitor in preparing the medicine for treating the diabetic foot, and the TGF-beta inhibitor is proved to be capable of promoting the cells to maintain the mitochondrial membrane potential to be stable under the conditions of high glucose and low nutrition; and the intracellular active oxygen level is reduced, so that the cells maintain good proliferative activity and vascularization function. The function-enhanced endothelial cells obtained through induction and domestication culture of the TGF-beta inhibitor can survive for a long time in limbs of the ischemic diabetic foot of a mouse and form new vessels, and the treatment effect of endothelial cell transplantation on the ischemic diabetic foot is improved. According to the invention, the application range of the TGF-beta inhibitor is widened, a more effective method is provided for the cell therapy of diabetic foot, and the TGF-beta inhibitor has a good prospect.

A method of preparing a transplant site for cellular transplantation in a mammal includes the steps of inserting a foreign body comprising a biomaterial into an internal tissue; and removing the foreign body after the tissue surrounding the foreign body has undergone an inflammatory response but before significant fibrous encapsulation has occurred, leaving a neovascularized lumen suitable to receive transplanted cells or islets.

The present invention provides methods for enhancing cellular transplantation by exposing cells in vitro or ex vivo, or a recipient of cells, to a small molecule hepatocyte growth factor / scatter factor mimetic. Exemplary compounds are described.

The invention belongs to the field of biological medicine research, and particularly provides application of a transcription factor in one or more of the following items: preparing a medicine for treating retinal diseases; preparing a retina ganglion cell regeneration product; preparing a product for inducing adult cells to be reprogrammed into retinal ganglion cells; and preparing retinal ganglion cells. The transcription factor is selected from any one or more of Brn3B, Sox4, Atoh7, Sox11 and Isl1. A cell material used for regenerating the retinal ganglion cell is an endogenous cell of the retina ganglion cell, and compared with a cell transplantation mode, the retina ganglion cell has no immunological rejection and tumor formation risk; and the virus expression gene is simple, convenient and easy to popularize.

The invention relates to application of umbilical cord Wharton jelly originated mesenchymal stem cells used as cellular transplantation materials for treating heart failures caused by coronary heart diseases and dilated cardiomyopathies, wherein the heart failures include chronic ischemic heart failures caused by myocardial infarction, final-stage ischemic heart failures, and the heart failures caused by secondary cardiomyopathies after primary dilated cardiomyopathies and myocarditis.